We’re participating in the #JefferiesHealthcare conference this week. Tune in to the fireside chat webcast tomorrow at 2:30pm ET. Register and listen here https://bit.ly/3KmVM28
Cogent Biosciences’ Post
More Relevant Posts
-
Today we shared additional clinical data from Part 1 of our ongoing SUMMIT trial evaluating bezuclastinib in patients with #NonAdvSM. Stop by our poster at #EHA2024 today to learn more. You can also read the press release here https://bit.ly/4c1CLOO and find the poster on our website https://bit.ly/4coyc0Z.
-
-
The Cogent team is excited about the scientific content at #EHA2024 in Madrid and we’re thrilled to participate in discussions with the hematology community. Come by our booth to learn more!
-
-
Our G&A team enjoyed an evening filled with fun, laughter, and friendly competition. Moments like these remind us of the strong bonds we share and the amazing people we work with every day. 🎳 #TeamOuting #WorkFun #GATeam
-
-
We made it to Chicago! Come meet the team in the exhibit hall. You can also check out today’s PEAK lead-in update poster here https://bit.ly/45dYArV and read the details from our press release https://bit.ly/4dWlZlx. #GIST #raredisease
-
-
We’re thrilled to welcome Cole Pinnow as our new Chief Commercial Officer! Read more here. https://bit.ly/3yvW2cz
-
-
Today we shared positive updated lead-in data from our ongoing Phase 3 PEAK trail with bezuclastinib in combination with sunitinib in GIST patients. The data are being presented at #ASCO24. Read more here https://bit.ly/4dWlZlx.
-
-
Cogent is excited to engage with attendees at the American Initiative in Mast Cell Diseases (AIM) meeting this weekend in Boston. We’re proud to support this important educational event for the patient and clinical communities. Come meet the team at our Clinical Trial Basecamp to learn more. #ASM #NonAdvSM #MastCellDiseases #mastocytosis
-
-
Earlier this week we reported our first quarter 2024 financial results. Read the full announcement here. https://bit.ly/4dr74Q5
-
